You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.
The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
The researchers plan to use the method in clinical research, designing noninvasive prenatal tests for single-gene disorders like beta thalassemia.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Ampath will be one of the first laboratories in South Africa to offer a CE-IVD accredited noninvasive prenatal testing center and will act as a hub for such services.
Until March 2018, when the patent in question expires, Cenata will have its Harmony test performed by Medirex in Slovakia.
Illumina has filed a new lawsuit against Premaitha, claiming it infringes on an Illumina patent related to noninvasive prenatal testing.